EUCTR2015-004427-31-SE进行中（未招募）不适用
Tenofovir Alafenamide Fumarate (TAF) effect on residual intrathecal immune activation
Gothenburg University0 个研究点开始时间: 2016年1月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Stable antiretroviral therapy with TDF/FTC or ABC/3TC + 3rd agent (PI/r, NNRTI, or INI) for more than18 months.
- •2. Plasma HIV-RNA < 50 copies/mL for more than 12 months.
- •3. No neurological symptoms or severe neurocognitive impairment.
- •4. No pre-treatment central nervous system opportunistic infection/tumour or HIV-associated dementia.
- •5. Lumbar puncture performed in the longitudinal cerebrospinal fluid study (University of Gothenburg) between 6 and 18 months before study entry.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Not on successful antiretroviral therapy.
研究者
相似试验
招募中
不适用
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.Chronic hepatitis B and cirrhosisJPRN-UMIN000034362ippon Medical Chiba Hokusoh Hospital500
进行中（未招募）
1 期
Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF)HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003345-29-GBKings College Hospital NHS Foundation Trust40
招募中
1 期
The TAF-MS studyMultiple sclerosisCTIS2023-503814-62-00Helse Bergen HF50
招募中
不适用
Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patientsChronic hepatitis BJPRN-UMIN000029099Toranomon branch Hospital650
招募中
不适用
TAF (drug) for hepatitis B virus infectioCTRI/2022/01/039541Institute of Liver and Biliary Sciences